'Survivor' celebrity and philanthropist Ethan Zohn is reporting to Everyday Health that despite being relatively confined to his New York City apartment, he is gaining strength every day and his heath is improving following the three months of Adcetris treatment and the stem cell transplantation he underwent back in February.
Zohn was diagnosed with recurrent Hodgkin's lymphoma in September, and was therefore given more aggressive treatment. High dose radiation and chemotherapy knocked out his immune system and the donor immune cells he received can still reject him in a serious potential complication known as graft-versus-host disease.
Because he is growing a new immune system, "I’m really susceptible to infection and germs and something called graft-vs.-host-disease, so I’m on a pretty aggressive regimen of medicine to keep me healthy, and I have all these restrictions placed on me," he told Everyday Health.
You can read more of Zohn's chat at Everyday Health.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...